A First Human Dose Study Investigating Safety, Tolerability, and Pharmacokinetics of Subcutaneous Single Ascending Doses of NNC0650-0013 in Healthy Male Participants
Latest Information Update: 25 Nov 2024
At a glance
- Drugs NNC0650 0013 (Primary) ; NNC0650 0013 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors Novo Nordisk
Most Recent Events
- 19 Nov 2024 Status changed from recruiting to completed.
- 08 Mar 2024 New trial record